OBJECTIVE: To comprehensively review and critically assess the literature on vaginal
estrogen and its alternatives for women with genitourinary syndrome of menopause and to …

There is increasing attention about managing the adverse effects of adjuvant therapy
(Chemotherapy and anti-estrogen treatment) for breast cancer survivors (BCSs) …

Objective: The objective of this document is to generate a practice guideline for the
management and treatment of symptoms of the menopause. Participants: The Treatment of …

Unlike hot flushes and night sweats which resolve spontaneously in time, atrophic symptoms
affecting the vagina and lower urinary tract are often progressive and frequently require …

Importance Nearly half of postmenopausal women report bothersome vulvovaginal
symptoms, but few data support the efficacy of 2 commonly recommended treatments …

Introduction: Recent improvements in the survival of hormone-responsive breast cancer are
strongly associated with therapeutic advances, particularly with the uptake of adjuvant …

Objective The goal of this study was to investigate sexual function in postmenopausal breast
cancer patients treated with aromatase inhibitors. Methods A population-based, cross …

Objective Menopause and its transition represent significant risk factors for the development
of vulvovaginal atrophy-related sexual dysfunction. The objective of this study was to review …

Women with estrogen-positive breast cancers receive endocrine treatment such as
tamoxifen and aromatase inhibitors (AI) for 5–10 years. An important side effect of these …

Introduction and hypothesis The aim of this study is to provide an evidence-based definition
of vaginal atrophy (VA) and present an overview of subjective and objective measurements …